Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function.
The conclusion that prolactin plays a role in immune and hematopoietic function was initially based upon observations in hormone deficient animals. The multiple cell function defects associated with hypophysectomy or bromocriptine treatment were reversed by administration of prolactin. Since these initial observations, an increasing body of literature supports prolactin having a role in the immune and hematopoietic system. A recombinant form of human prolactin (r-hPRL) has been produced and evaluated in a wide variety of preclinical models. Both in vitro and in vivo studies suggest that r-hPRL can enhance cell function, accelerate lymphoid and myeloid reconstitution and promote hematopoiesis. The multi-lineage effect of r-hPRL makes it an attractive candidate for clinical situations presenting with immune deficiency or myelosuppression.
Richards
S M
SM
Department of Cell and Protein Therapeutics, Genzyme Corporation, Boston, MA, USA.
Murphy
W J
WJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D011388:Prolactin / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects; D015215:Zidovudine / Q000633:toxicity
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D015215:Zidovudine; D011388:Prolactin